Pfizer Inc

Several funds dive into financial services and undervalued healthcare stocks.

Recent results from some of the most undervalued large drugmakers we cover.

In part two of our three-part special report on value investing, our analysts share insights gleaned from fund manager interviews.

The Fed’s meeting is scheduled for next week, sparking speculations of another interest-rate cut.

There were fewer opportunities as the third quarter ended.

These stocks have a wide or narrow economic moat and an uncertainty rating of low or medium.

We find several actionable ideas that yield more than the S&P 500.

Check out these pharmaceutical stocks for both capital appreciation and dividend yield.

We recap the week on Morningstar.com and note the most popular stocks, funds, and ETFs.

These stocks are good choices whether you're looking for dividend growth, down-market defense, or inflation protection.

These high-quality names are trading at 5-star levels.

We think these wide-moat companies are poised to experience meaningful economic benefits in the future.

We recap the week on Morningstar.com and note the most popular stocks, funds, and ETFs.

The divestment of the generics business should strengthen Pfizer's competitive positioning.

We see opportunity within the consumer cyclical sector.

Innovation and M&A may drive these firms' fortunes.

Raise a glass: Morningstar turns 35 today. Let's celebrate with some of our favorite mutual fund, ETF, and stock ideas.

We expect these high-yielders to sustain their dividends in the future. Plus, they’re cheap.

Seven of the top 10 dividend-yielding names are undervalued.

This week on the podcast, finding "fantastic" funds, Vanguard's inflation hedge, and the changing face of value investing.